Skip to main content

Table 2 Statin medication use characteristics among uveitis cases and control subjects

From: Statin use and ocular inflammatory disease risk

  Uveitis cases Control subjects OR (95% CI) OR (95% CI) a p value
Number of subjects 92 920    
Statin use
 No 84 (91.3) 819 (89.0) 1.00 (reference) 1  
 Yes 8 (8.7) 101 (11.0) 0.79 (0.38 to 1.63) 0.50 (0.20 to 1.23) 0.13
 Current use 4 (4.4) 53 (5.8) 0.76 (0.28 to 2.06) 0.46 (0.15 to 1.46) 0.19
 Past use 4 (4.4) 48 (5.2) 0.83 (0.30 to 2.26) 0.54 (0.18 to 1.67) 0.29
Duration of use (month)
 No use 84 (91.3) 819 (89.0) 1.00 (reference) 1  
 <12 5 (5.4) 44 (4.8) 1.10 (0.45 to 2.70) 0.74 (0.27 to 2.07) 0.57
 12 to 23 2 (2.2) 23 (2.5) 0.86 (0.21 to 3.50) 0.45 (0.10 to 2.01) 0.29
 >23 1 (1.1) 34 (3.7) 0.31 (0.04 to 2.21) 0.19 (0.02 to 1.52) 0.12
  1. Values are expressed as number (percentage) of individuals unless otherwise indicated. Analyses are for OID versus no OID. OID, ocular inflammatory disease; OR, odds ratio. aAdjusted for diabetes, lipid metabolism disorders, hypertension, cardiovascular disease, cerebrovascular disease, and arterial disease.